fibroblast growth factor binding protein 3Genealiases: C10orf13 · FGF-BP3
Q-omics provides the consensus-scored FGFBP3 profile across patient tissues and cancer cell-line models. FGFBP3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FGFBP3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FGFBP3 RNA expression shows 18,436 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where FGFBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGFBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGFBP3 survival associations across molecular data types. FGFBP3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGFBP3 RNA expression–survival associations across cancer types. High FGFBP3 expression shows unfavorable associations in ACC, but favorable associations in OV, UCS, LGG, GBM and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FGFBP3 RNA expression.
This table summarizes FGFBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FGFBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGFBP3 shows lower tumor expression in THCA, KIRC, KICH, KIRP and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher FGFBP3 RNA expression in normal versus tumor tissue (log2 FC = −1.880, t-test p < 0.001).
This table shows molecular features associated with FGFBP3 in patient tissues and cancer cell lines. In patient samples, FGFBP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FGFBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
